Ivkovic Milos, Reiss-Zimmermann Martin, Katzen Heather, Preuss Matthias, Kovanlikaya Ilhami, Heier Linda, Alperin Noam, Hoffmann Karl T, Relkin Norman
Weill Cornell Medical College, New York, NY, USA.
University of Leipzig, Leipzig, Germany.
Fluids Barriers CNS. 2015 Apr 2;12:9. doi: 10.1186/s12987-015-0004-z.
The objective was to identify changes in quantitative MRI measures in patients with idiopathic normal pressure hydrocephalus (iNPH) occurring in common after oral acetazolamide (ACZ) and external lumbar drainage (ELD) interventions.
A total of 25 iNPH patients from two clinical sites underwent serial MRIs and clinical assessments. Eight received ACZ (125-375 mg/day) over 3 months and 12 underwent ELD for up to 72 hours. Five clinically-stable iNPH patients who were scanned serially without interventions served as controls for the MRI component of the study. Subjects were divided into responders and non-responders to the intervention based on gait and cognition assessments made by clinicians blinded to MRI results. The MRI modalities analyzed included T1-weighted images, diffusion tensor Imaging (DTI) and arterial spin labelling (ASL) perfusion studies. Automated threshold techniques were used to define regions of T1 hypo-intensities.
Decreased volume of T1-hypointensities and decreased mean diffusivity (MD) within remaining hypointensities was observed after ACZ and ELD but not in controls. Patients responding positively to these interventions had more extensive decreases in T1-hypointensites than non-responders: ACZ-responders (4,651 ± 2,909 mm(3)), ELD responders (2,338 ± 1,140 mm(3)), ELD non-responders (44 ± 1,188 mm(3)). Changes in DTI MD within T1-hypointensities were greater in ACZ-responders (7.9% ± 2%) and ELD-responders (8.2% ± 3.1%) compared to ELD non-responders (2.1% ± 3%). All the acetazolamide-responders showed increases in whole-brain-average cerebral blood flow (wbCBF) estimated by ASL (18.8% ± 8.7%). The only observed decrease in wbCBF (9.6%) occurred in an acetazolamide-non-responder. A possible association between cerebral atrophy and response was observed, with subjects having the least cortical atrophy (as indicated by a positive z-score on cortical thickness measurements) showing greater clinical improvement after ACZ and ELD.
T1-hypointensity volume and DTI MD measures decreased in the brains of iNPH patients following oral ACZ and ELD. The magnitude of the decrease was greater in treatment responders than non-responders. Despite having different mechanisms of action, both ELD and ACZ may decrease interstitial brain water and increase cerebral blood flow in patients with iNPH. Quantitative MRI measurements appear useful for objectively monitoring response to acetazolamide, ELD and potentially other therapeutic interventions in patients with iNPH.
目的是确定特发性正常压力脑积水(iNPH)患者在口服乙酰唑胺(ACZ)和腰大池外引流(ELD)干预后常见的定量MRI测量值的变化。
来自两个临床地点的25例iNPH患者接受了系列MRI检查和临床评估。8例患者在3个月内服用ACZ(125 - 375毫克/天),12例患者接受了长达72小时的ELD。5例临床稳定的iNPH患者在未进行干预的情况下接受了系列扫描,作为该研究MRI部分的对照。根据对MRI结果不知情的临床医生进行的步态和认知评估,将受试者分为干预反应者和无反应者。分析的MRI模态包括T1加权图像、扩散张量成像(DTI)和动脉自旋标记(ASL)灌注研究。使用自动阈值技术定义T1低信号区域。
ACZ和ELD治疗后观察到T1低信号体积减小以及剩余低信号区域内的平均扩散率(MD)降低,但对照组未出现此情况。对这些干预反应良好的患者,其T1低信号区域的减小程度比无反应者更大:ACZ反应者(4,651±2,909立方毫米)、ELD反应者(2,338±1,140立方毫米)、ELD无反应者(44±1,188立方毫米)。与ELD无反应者(2.1%±3%)相比,ACZ反应者(7.9%±2%)和ELD反应者(8.2%±3.1%)的T1低信号区域内DTI MD的变化更大。所有ACZ反应者的全脑平均脑血流量(wbCBF)通过ASL估计均增加(18.8%±8.7%)。唯一观察到的wbCBF降低(9.6%)发生在一名ACZ无反应者身上。观察到脑萎缩与反应之间可能存在关联,皮质萎缩最少的受试者(通过皮质厚度测量的正z评分表示)在ACZ和ELD治疗后显示出更大的临床改善。
口服ACZ和ELD后,iNPH患者大脑中的T1低信号体积和DTI MD测量值降低。治疗反应者的降低幅度大于无反应者。尽管作用机制不同,但ELD和ACZ均可降低iNPH患者的脑间质水含量并增加脑血流量。定量MRI测量似乎有助于客观监测iNPH患者对乙酰唑胺、ELD以及可能的其他治疗干预的反应。